Skip to main content
. 2022 Sep 22;14(19):4606. doi: 10.3390/cancers14194606

Table 4.

Median overall survival (months) of patients treated with Docetaxel according to NLR.

NLR Low (≤5) NLR High (>5) HR (95% CI) * p-Value
Baseline 29.9 (24.2–41.1) 35.8 (16.8–NR) 0.78 (0.37–1.6) 0.50
At 12 weeks 35.8 (29.9–NR) 25.6 (16.2–NR) 1.27 (0.62–2.61) 0.51

* Hazard Ratio (HR) adjusted on docetaxel treatment, previous prostatectomy, Eastern Cooperative Group (ECOG) performance status, prostate specific antigen (PSA) level, hemoglobin level (Hb), total alkaline phosphatase (tALP).